Article
Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements.
The Journal of clinical investigation - 16 Jan 2026
DiNapoli Sarah R, Wright Katharine M, Mog Brian J, Pearlman Alexander H, Nichakawade Tushar D, Marcou Nikita, Hsiue Emily Han-Chung, Hwang Michael S, Douglass Jacqueline, Liu Qiang, Watson Evangeline, Dal Molin Marco, Cohen Joshua D, Popoli Maria, Paul Suman, Konig Maximilian F, Wyhs Nicolas, Azurmendi P Aitana, Glavaris Stephanie, Ge Jiaxin, Awosika Tolulope O, Liu Jin, Gabrielson Kathleen L, Gabelli Sandra B, Pardoll Drew M, Bettegowda Chetan, Papadopoulos Nickolas, Kinzler Kenneth W, Zhou Shibin, Vogelstein Bert
Abstract excerpt
Mutation-associated neoantigens (MANAs) are highly cancer-specific targets for immunotherapy where peptides derived from intracellular mutant proteins are presented on the cell surface via HLA molecules. T cell-engaging bispecific antibodies and CAR T cells can target MANAs to eliminate cancer cells via T cell activation. However, the low antigen density of MANAs on the cell surface can limit therapeutic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.